Evonik's Board Said No to Talks, but Left the Door Ajar on Information
Published on 10/31/2026 at 15:03 | Editorial boerse-global.de
Evonik's rejection of takeover negotiations with BASF has not closed the door entirely — it has merely narrowed what the two sides are prepared to discuss. The board declined talks over a voluntary public takeover offer after reviewing BASF's letter of 22 October, yet simultaneously agreed to a purely informational, confidential exchange. That distinction now sits at the heart of how investors should weigh the stock.
For anyone holding Evonik shares, the question is no longer whether BASF is interested. It is whether an uncommitted exchange of information can evolve into something more substantial. A deal remains neither agreed nor ruled out.
What the Reported Terms Actually Represent
Reuters reported on 23 October, citing two people familiar with the discussions, that BASF had raised its offer to EUR 24 per share. A valuation of EUR 11.18 billion for Evonik was also cited on Wednesday. These are reported offer conditions, not a negotiated takeover price — a distinction that matters enormously for anyone treating the figure as a floor.
Friday's closing price of EUR 21.06 sat below the reported offer level. That gap should not be read as readily available upside. Anyone positioning for it also assumes the risk that no agreement is ever reached. Equally, dismissing the transaction entirely because talks were refused would be premature.
Should investors sell immediately? Or is it worth buying Evonik?
BASF, according to Reuters, responded to Evonik's refusal with incomprehension, pointing to its EUR 24.00 per-share offer along with commitments covering employees and sites. Those assurances could themselves become a topic of discussion, though whether they would shift Evonik's stance cannot be inferred from the rejection. Nor is a higher price either mandatory or promised.
Price Discipline Meets a Rejection
The counterweight to any takeover optimism is explicit. BASF chief executive Markus Kamieth said on Wednesday that his company would not pay "excessive prices" for Evonik. BASF reaffirmed its interest in a deal at the same time — meaning interest and willingness to pay are, by the company's own framing, not unlimited.
That combination of Evonik's refusal and BASF's stated price ceiling is the serious bear case. Investors should not assume that every rejection automatically produces a sweetened bid. Kamieth's remark argues against any such certainty, without announcing a retreat.
The risk, then, is a double disappointment: business performance missing expectations while hopes for better takeover terms fade. That is a scenario rather than a foregone conclusion, but it explains why an investment case should not rest solely on the distance to the reported offer price.
A Second Front: Syneqt
Even a deal would not settle every strategic question. Evonik subsidiary Syneqt insisted to Reuters on Tuesday on remaining independent, including under BASF ownership. Evonik had earmarked the unit for sale and, according to earlier statements, planned to begin the disposal process next year. Alongside the takeover question, the group's future shape therefore remains under discussion.
November 3 as the Standalone Yardstick
The next concrete date is the release of the third-quarter 2026 interim report on 03.11.2026. It could give investors an additional basis for valuing Evonik independently of any potential buyer. No decision on the takeover conflict is scheduled for that date.
Evonik at a turning point? This analysis reveals what investors need to know now.
Strong quarterly figures would make the board's refusal economically more comprehensible. Investors would then have less reason to measure the stance exclusively against the prospect of a higher offer — particularly relevant for those who want to hold Evonik without a sale to BASF. Conversely, disappointing numbers would not automatically push BASF to pay more, nor force Evonik to the table.
A favourable outcome would see the results underpin the standalone valuation while the confidential exchange keeps a later rapprochement alive. Operational substance on one side, a still-possible transaction on the other. Yet the offered information exchange creates no negotiating situation on its own; in the best case it is a starting point. Only a confirmed change in the state of discussions would justify repricing the odds of a deal.
Until then, two layers should be kept apart: what Evonik is worth on its own, and what a transaction might add. For the latter, the decisive signal is not another restatement of interest but a visible shift from information to negotiation.
Ad
Evonik Stock: New Analysis - 31 October
Fresh Evonik information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
